Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
Clearside Biomedical, Inc. (NASDAQ:CLSD) will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clearside Biomedical, Inc. (NASDAQ:CLSD) will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time. The company's President and CEO, George Lasezkay, and Chief Medical Officer, Thomas A. Ciulla, will discuss Clearside's innovative SCS injection platform that targets therapies to the back of the eye. This platform aims to improve vision preservation and enhance treatment delivery for sight-threatening diseases. Live and archived webcasts will be available on their website.
Details
News Market Reaction – CLSD
The recorded move for CLSD in the trading session of this news was +3.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time, in New York, NY.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.